An interventional study of Single Vision Lens (SVL) and Myopia Control Lens (MCL) in Myopia, sponsored by Essilor International. Completed at 1 site in Singapore. Open to participants aged 8 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myopia by EssilorLuxottica — 14 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.
Among the 28 studies in Myopia by EssilorLuxottica, this one is the 23rd largest by enrollment, is one of 9 that started in 2025, is one of 28 with no phase, and was the 25th registered.
1,160 studies on the registry are indexed under Myopia; 226 are open to participants now.
Browse Myopia studies →14 of the 28 studies in Myopia by EssilorLuxottica are open now, in 5 countries. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Essilor International · Sites in China
Ages 6–12
By country, each count listing its studies:
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 8 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2025.
This study's enrollment of 20 is below the median of 79 across 924 interventional studies indexed under Myopia.
Median enrollment 52 across the 28 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
6 of the studies in Myopia by EssilorLuxottica that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT06850168Essilor InternationalClinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression | 2027-10 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Myopia by EssilorLuxottica, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how children with myopia aged 8 to 15 years move their eyes and heads during near-vision tasks while wearing different spectacle lenses, and if wearing myopia control spectacle lenses for one month is related to change in eye length (axial length). The main questions it aims to answer are:
This study compares commercially available myopia control spectacle lenses with single-vision spectacle lenses to evaluate differences in eye gaze position, head movement patterns, and axial length.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single-arm, within-subject design; Each participant received both Single Vision Lens (SVL) and Myopia Control Lens (MCL) spectacles.
Device: Single Vision Lens (SVL) · Device: Myopia Control Lens (MCL)
Standard, commercially available single vision spectacle lenses worn on-site during near vision task assessment at Visit 2 and Visit 3.
Commercially available Stellest® spectacle lenses worn on-site during near vision task assessment at Visit 2 and Visit 3, and worn continuously for approximately 1 month between Visit 2 and Visit 3.
Change in eye gaze position
Eye gaze positions are derived from post-processed video recordings of participants performing near-vision tasks while wearing the study spectacles.
Time frame: Visit 1 (Baseline), Visit 2 (1-2 weeks), Visit 3 (1-month)
Change in axial length
Time frame: Visit 2 (Baseline), Visit 3 (1-month)
Change in head movement pattens
Head movement patterns are derived from post-processed video recordings of participants performing near-vision tasks while wearing the study spectacles.
Time frame: Visit 1 (Baseline), Visit 2 (1-2 weeks), Visit 3 (1-month)
Change in scores of the Pediatric Refractive Error Profile (PREP) version 2 questionnaire
Child-reported scores ranging from 0 to 100, with higher scores indicate better vision-related quality of life. Parent-reported scores ranging from 1-10, with higher scores indicate better vision-related quality of life.
Time frame: Visit 2 (Baseline), Visit 3 (1-month)
Plan to share: No
Ran from Apr 2025 to primary completion in Mar 2026, 11 months.
Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 11 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.